Cost Effectiveness of Lacosamide in the Adjunctive Treatment of Patients with Refractory Focal Epilepsy in Belgium

Simoens, Steven; De Naeyer, Liesbet; Dedeken, Peter
April 2012
CNS Drugs;2012, Vol. 26 Issue 4, p337
Academic Journal
Objectives: Lacosamide is an anti-epileptic drug, indicated as adjunctive therapy for patients with focal seizures with or without secondary generalization. This study aims to assess the cost effectiveness of standard antiepileptic drug therapy plus lacosamide 300 mg/day compared with standard therapy alone from the perspective of the Belgian healthcare payer. Methods: The treatment pathway of a hypothetical cohort of 1000 patients over 2 years was simulated using a decision tree. Data about health state probabilities, seizure frequency and utility values were taken from lacosamide trials or from the literature. Effectiveness measures included the number of seizures avoided and the number of quality-adjusted life-years gained. Unit costs were taken from national references. Resource use was estimated by a panel of eight neurologists with extensive experience in epilepsy. The price year was 2008. Deterministic and probabilistic sensitivity analyses were conducted. Results: Over a 24-month period, standard anti-epileptic drug therapy plus lacosamide led to a reduction of seven seizures, an increase of 0.038 qualityadjusted life-years and a cost decrease of €3619 per patient compared with standard therapy alone. Using a willingness to pay of €30 000 per qualityadjusted life-year, the net monetary benefit of standard anti-epileptic drug therapy plus lacosamide amounted to &3x20AC;4754. The probability of standard anti-epileptic drug therapy plus lacosamide being cost effective was 97.3%, 99.8%, 99.9% and 100% at 6, 12, 18 and 24 months, respectively. Conclusion: In patients with difficult-to-treat epilepsy, standard anti-epileptic drug therapy plus lacosamide appears to be a cost-effective option in Belgium.


Related Articles

  • Adjunctive lacosamide the way forward in RFE in Belgium.  // PharmacoEconomics & Outcomes News;4/14/2012, Issue 651, p10 

    The article discusses research on the cost effectiveness of lacosamide in the adjunctive treatment of patients with refractory focal epilepsy in Belgium, referencing a study by S. Simoens and colleagues published on the April 1, 2012 issue of "CNS Drugs."

  • Too Cool for School. Lipsitz, Katherine H. // WE Magazine;Jul/Aug99, Vol. 3 Issue 4, p106 

    Reveals how the author who works for a nonprofit organization for children with or affected by HIV/AIDS struggled with her epilepsy. Advice from a doctor; Miseries of an epileptic.

  • Treatment of Patients with Refractory Seizures. Kirchner, Jeffrey T. // American Family Physician;11/1/1999, Vol. 60 Issue 7, p2143 

    Discusses the therapeutic considerations for patients who have refractory seizures. Performance of magnetic resonance imaging; Basis for the choice of antiepeliptic drug; Options for the treatment of refractory seizure.

  • NICE cost-effectiveness evaluations questioned in report.  // PharmacoEconomics & Outcomes News;Mar2014, Vol. 699 Issue 1, p2 

    The article focuses on a report published by the University College London School of Pharmacy concerning the cost-effectiveness assessments performed by the British National Institute for Health and Care Excellence (NICE) on new drugs in 2008-2013.

  • FOREWORD. Ben-Menachem, Elinor // CNS Drugs;2011 Supplement 1, Vol. 25, p1 

    An introduction is presented in which the editor discusses various reports within the issue on topics including therapeutic options for refractory partial seizures, clinical cases of patients with difficult-to-treat epilepsy, and efficacy of lacosamide as adjuvant antiepileptic therapy.

  • Identifying and prioritising epilepsy treatment uncertainties. R H Thomas // Journal of Neurology, Neurosurgery & Psychiatry;Aug2010, Vol. 81 Issue 8, p918 

    OBJECTIVE: To identify and prioritise uncertainties regarding epilepsy treatment from people with epilepsy, their carers and epilepsy clinicians. BACKGROUND: Failure to acknowledge and address genuine treatment uncertainties has caused unnecessary iatrogenic harm. The authors define an...

  • POE01 Outcome of medication change in patients with refractory epilepsy. S H Wong // Journal of Neurology, Neurosurgery & Psychiatry;Nov2010, Vol. 81 Issue 11, pe45 

    BACKGROUND: Despite the low probability of achieving seizure-freedom in refractory epilepsy patients and clinicians may be inclined to try new or previously untried medications. We assessed the outcome of consecutive medication changes in patients with refractory epilepsy, seen in an adult...

  • De Novo Sustained Refractory Status Epilepticus and Encephalopathy: A Retrospective Case Series. Fong, Joanna S.; Hantus, Stephen; Erbayat Altay, Ebru; Tuxhorn, Ingrid // Journal of Child Neurology;12/1/2010, Vol. 25 Issue 12, p1535 

    Refractory status epilepticus is a devastating persistent seizure state with a poor prognosis that requires emergency medical management. Recent studies have reported de novo, idiopathic refractory status epilepticus of unclear etiology in healthy young patients followed by severe neurologic...

  • Nutritional Support of Epilepsy. Volpenhein, Linda M. // MMRC Health Educator Reports;2008, p1 

    The article identifies the health and therapeutic benefits of nutrition among epileptics. Epilepsy is condition due to the damage to a group of cells in the brain before or after birth due to severe oxygen shortage during labor or delivery. It is sometimes due to head trauma, toxic reaction....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics